Terms: = Breast cancer AND CDK4, PSK-J3, 1019, ENSG00000135446, MGC14458, CMM3, P11802 AND Prognosis
118 results:
1. Mutational Analysis of Circulating Tumor DNA in Patients With Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced breast cancer Receiving Palbociclib: Results From the TREnd Trial.
Migliaccio I; Romagnoli D; Galardi F; De Luca F; Biagioni C; Curigliano G; Criscitiello C; Minisini AM; Moretti E; Risi E; Guarducci C; Nardone A; Biganzoli L; Benelli M; Malorni L
JCO Precis Oncol; 2024 Feb; 8():e2300285. PubMed ID: 38427931
[TBL] [Abstract] [Full Text] [Related]
2. The association between HER2-low status and survival in patients with metastatic breast cancer treated with Cyclin-dependent kinases 4 and 6 inhibitors: a systematic review and meta-analysis.
Guven DC; Sahin TK
Breast Cancer Res Treat; 2024 Apr; 204(3):443-452. PubMed ID: 38240935
[TBL] [Abstract] [Full Text] [Related]
3. ER-positive and BRCA2-mutated breast cancer: a literature review.
Li PC; Zhu YF; Cao WM; Li B
Eur J Med Res; 2024 Jan; 29(1):30. PubMed ID: 38184581
[TBL] [Abstract] [Full Text] [Related]
4. Efficacy, safety, and prognosis prediction in patients treated with ribociclib in combination with letrozole: Final results of phase 3b RIBECCA study in hormone receptor positive, human epidermal growth factor receptor-2 negative, locally advanced or metastatic breast cancer.
Fasching PA; Decker T; Hartkopf A; Nusch A; Heinrich BJ; Kurbacher C; Fuchs R; Tesch H; Krabisch P; Huober J; Kuemmel S; Brucker S; Janni W; Schneeweiss A; Schuler M; Fehm T; Lüftner D; Quiering C; Voges C; Kreuzeder J; Reinisch M
Eur J Cancer; 2024 Feb; 198():113480. PubMed ID: 38154393
[TBL] [Abstract] [Full Text] [Related]
5. Addressing unmet need in the management of patients with ER+/HER2-, ESR1-mutated metastatic breast cancer: clinician's perspective.
Rugo HS
Clin Adv Hematol Oncol; 2023 Dec; 21(12):623-632. PubMed ID: 38039056
[TBL] [Abstract] [Full Text] [Related]
6. C9orf142 transcriptionally activates MTBP to drive progression and resistance to cdk4/6 inhibitor in triple-negative breast cancer.
Liao L; Deng L; Zhang YL; Yang SY; Andriani L; Hu SY; Zhang FL; Shao ZM; Li DQ
Clin Transl Med; 2023 Nov; 13(11):e1480. PubMed ID: 38009308
[TBL] [Abstract] [Full Text] [Related]
7. IGF2BP2 Drives Cell Cycle Progression in Triple-Negative breast cancer by Recruiting EIF4A1 to Promote the m6A-Modified CDK6 Translation Initiation Process.
Xia T; Dai XY; Sang MY; Zhang X; Xu F; Wu J; Shi L; Wei JF; Ding Q
Adv Sci (Weinh); 2024 Jan; 11(1):e2305142. PubMed ID: 37983610
[TBL] [Abstract] [Full Text] [Related]
8. Immunoexpression of HER2 pathway related markers in HER2 invasive breast carcinomas treated with trastuzumab.
Franco AFDV; Malinverni ACM; Waitzberg AFL
Pathol Res Pract; 2023 Dec; 252():154917. PubMed ID: 37977031
[TBL] [Abstract] [Full Text] [Related]
9. Circulating Tumor Cells Prediction in Hormone Receptor Positive HER2-Negative Advanced breast cancer: A Retrospective Analysis of the MONARCH 2 Trial.
Gerratana L; Kocherginsky M; Davis AA; D'Amico P; Reduzzi C; Puglisi F; Cristofanilli M
Oncologist; 2024 Feb; 29(2):123-131. PubMed ID: 37935631
[TBL] [Abstract] [Full Text] [Related]
10. More Than Meets the Eye: A Case of breast cancer Switching from Being Luminal-Androgen-Receptor-Positive to Being Hormone-Receptor-Positive.
Martorana F; Di Grazia G; Rosano GN; Vecchio GM; Conti C; Nucera S; Magro G; Vigneri P
Medicina (Kaunas); 2023 Oct; 59(10):. PubMed ID: 37893593
[TBL] [Abstract] [Full Text] [Related]
11. Recent Developments in the Therapeutic Landscape of Advanced or Metastatic Hormone Receptor-Positive breast cancer.
Lee EY; Lee DW; Lee KH; Im SA
Cancer Res Treat; 2023 Oct; 55(4):1065-1076. PubMed ID: 37817306
[TBL] [Abstract] [Full Text] [Related]
12. LncRNA EILA promotes cdk4/6 inhibitor resistance in breast cancer by stabilizing cyclin E1 protein.
Cai Z; Shi Q; Li Y; Jin L; Li S; Wong LL; Wang J; Jiang X; Zhu M; Lin J; Wang Q; Yang W; Liu Y; Zhang J; Gong C; Yao H; Yao Y; Liu Q
Sci Adv; 2023 Oct; 9(40):eadi3821. PubMed ID: 37801505
[TBL] [Abstract] [Full Text] [Related]
13. [Targeted systemic treatments and locoregional radiotherapy for breast cancer: Can we expect a benefit from the potentiation of local treatment?].
Camps Maléa A; Hennequin C; Rivera S
Cancer Radiother; 2023 Sep; 27(6-7):535-541. PubMed ID: 37558607
[TBL] [Abstract] [Full Text] [Related]
14. Impact of BMI in Patients With Early Hormone Receptor-Positive breast cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial.
Pfeiler G; Hlauschek D; Mayer EL; Deutschmann C; Kacerovsky-Strobl S; Martin M; Meisel JL; Zdenkowski N; Loibl S; Balic M; Park H; Prat A; Isaacs C; Bajetta E; Balko JM; Bellet-Ezquerra M; Bliss J; Burstein H; Cardoso F; Fohler H; Foukakis T; Gelmon KA; Goetz M; Haddad TC; Iwata H; Jassem J; Lee SC; Linderholm B; Los M; Mamounas EP; Miller KD; Morris PG; Munzone E; Gal-Yam EN; Ring A; Shepherd L; Singer C; Thomssen C; Tseng LM; Valagussa P; Winer EP; Wolff AC; Zoppoli G; Machacek-Link J; Schurmans C; Huang X; Gauthier E; Fesl C; Dueck AC; DeMichele A; Gnant M;
J Clin Oncol; 2023 Nov; 41(33):5118-5130. PubMed ID: 37556775
[TBL] [Abstract] [Full Text] [Related]
15. Detection of high-risk patients resistant to cdk4/6 inhibitors with hormone receptor-positive HER2-negative advanced and metastatic breast cancer in Japan (KBCSG-TR-1316).
Futamura M; Nakayama T; Yoshinami T; Oshiro C; Ishihara M; Morita M; Watanabe A; Tanigichi A; Tsukabe M; Shimoda M; Nitta K; Chihara Y; Yasojima H; Ouchi Y; Tokumaru Y; Masuda N
Breast Cancer; 2023 Nov; 30(6):943-951. PubMed ID: 37486454
[TBL] [Abstract] [Full Text] [Related]
16. Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancer.
Park YH; Im SA; Park K; Wen J; Lee KH; Choi YL; Lee WC; Min A; Bonato V; Park S; Ram S; Lee DW; Kim JY; Lee SK; Lee WW; Lee J; Kim M; Kim HS; Weinrich SL; Ryu HS; Kim TY; Dann S; Kim YJ; Fernandez DR; Koh J; Wang S; Park SY; Deng S; Powell E; Ravi RK; Bienkowska J; Rejto PA; Park WY; Kan Z
Genome Med; 2023 Jul; 15(1):55. PubMed ID: 37475004
[TBL] [Abstract] [Full Text] [Related]
17. FSIP1 enhances the therapeutic sensitivity to cdk4/6 inhibitors in triple-negative breast cancer patients by activating the Nanog pathway.
Chen G; Sun L; Gu X; Ai L; Yang J; Zhang Z; Hou P; Wang Y; Ou X; Jiang X; Qiao X; Ma Q; Niu N; Xue J; Zhang H; Yang Y; Liu C
Sci China Life Sci; 2023 Dec; 66(12):2805-2817. PubMed ID: 37460715
[TBL] [Abstract] [Full Text] [Related]
18. Oxidative phosphorylation is a metabolic vulnerability of endocrine therapy and palbociclib resistant metastatic breast cancers.
El-Botty R; Morriset L; Montaudon E; Tariq Z; Schnitzler A; Bacci M; Lorito N; Sourd L; Huguet L; Dahmani A; Painsec P; Derrien H; Vacher S; Masliah-Planchon J; Raynal V; Baulande S; Larcher T; Vincent-Salomon A; Dutertre G; Cottu P; Gentric G; Mechta-Grigoriou F; Hutton S; Driouch K; Bièche I; Morandi A; Marangoni E
Nat Commun; 2023 Jul; 14(1):4221. PubMed ID: 37452026
[TBL] [Abstract] [Full Text] [Related]
19. cdk4/6 Inhibition in the Metastatic Setting: Where Are We Headed?
Sakach E; Keskinkilic M; Wood S; Canning M; Kalinsky K
Curr Treat Options Oncol; 2023 Sep; 24(9):1103-1119. PubMed ID: 37314645
[TBL] [Abstract] [Full Text] [Related]
20. Autophagy and breast cancer: Connected in Growth, Progression, and Therapy.
Wu Q; Sharma D
Cells; 2023 Apr; 12(8):. PubMed ID: 37190065
[TBL] [Abstract] [Full Text] [Related]
[Next]